These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 15951629)

  • 1. Prostate cancer cell survival pathways activated by bone metastasis microenvironment.
    Tenta R; Sotiriou E; Pitulis N; Thyphronitis G; Koutsilieris M
    J Musculoskelet Neuronal Interact; 2005 Jun; 5(2):135-44. PubMed ID: 15951629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype.
    Loberg RD; Logothetis CJ; Keller ET; Pienta KJ
    J Clin Oncol; 2005 Nov; 23(32):8232-41. PubMed ID: 16278478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T; Nutahara K; Higashihara E
    J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of bone metastasis in prostate cancer: clinical implications.
    Msaouel P; Pissimissis N; Halapas A; Koutsilieris M
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):341-55. PubMed ID: 18471791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions.
    Loberg RD; Gayed BA; Olson KB; Pienta KJ
    J Cell Biochem; 2005 Oct; 96(3):439-46. PubMed ID: 15988761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy.
    Lee EC; Tenniswood MP
    J Cell Biochem; 2004 Mar; 91(4):662-70. PubMed ID: 14991758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
    Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer.
    Tahir SA; Yang G; Ebara S; Timme TL; Satoh T; Li L; Goltsov A; Ittmann M; Morrisett JD; Thompson TC
    Cancer Res; 2001 May; 61(10):3882-5. PubMed ID: 11358800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastases in prostate cancer: a targeted approach.
    Storey JA; Torti FM
    Curr Opin Oncol; 2007 May; 19(3):254-8. PubMed ID: 17414645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone.
    Hall CL; Dai J; van Golen KL; Keller ET; Long MW
    Cancer Res; 2006 Sep; 66(17):8648-54. PubMed ID: 16951179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cell adhesion changes on proliferation and survival during prostate cancer development and progression.
    Knudsen BS; Miranti CK
    J Cell Biochem; 2006 Oct; 99(2):345-61. PubMed ID: 16676354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.